PreTRM Volume Jumps 54% Sequentially as Florida Medicaid Adds Coverage
SERA sits 29% above its 52-week low of $1.56 on elevated volume (4.1× avg).
Summary
Sera reported Q3 2026 revenue of $42,000, up 163% from a year ago, with PreTRM test volume up 54% sequentially and roughly five-fold from 1Q26. Ordering providers rose 34% sequentially. Florida became the second Medicaid state to cover the test, bringing covered Medicaid lives to about 7 million, and Illinois pricing is set at $525 with no prior authorization. Cash and investments ended the quarter at $72.8 million against $7.3 million of quarterly operating burn, so runway extends well past 2027. The company also started its CE Mark submission for PreTRM Global in Europe and expanded its sales force 25% in the quarter. Net loss was $8.05 million, or $0.16 per share, roughly flat year over year. Watch for the potential multi-state pilot with a large commercial insurer, planned to start in fiscal 2027.
At the time of this announcement, SERA was trading at $2.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $79.5M. The 52-week trading range was $1.56 to $3.85. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: PR Newswire.